Among them, the most common immunotherapy is PD-1/PD-L1 immune checkpoint inhibitors, which have been administered to many patients with cancer and have achieved a high response rate and lasting remission, significantly improving the survival rate of patients with recurrent or refractory Hodgkin's lymphoma [2–4], non-small cell lung cancer (NSCLC) [5–7], melanoma [8–10], etc., showing broad application prospects. Here, CD274 is linked to non-small cell lung carcinoma.